Investigating neural dysfunction with abnormal protein deposition in Alzheimer’s disease through magnetic resonance spectroscopic imaging, plasma biomarkers, and positron emission tomography
Authors:
Open Access
- 22 December 2023
- journal article
- research article
- Published by Elsevier in NeuroImage: Clinical
- Vol. 41, 103560
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Institute of Radiological Sciences (000030248)
- Chiba University
- Japan Society for the Promotion of Science (JP19H01041, JP20K16681)
- Japan Agency for Medical Research and Development (JP19dm0207072, JP21zf0127004, JP22dk0207055, JP22dk0207063)
This publication has 45 references indexed in Scilit:
- In vivo 1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatmentBMC Neuroscience, 2009
- N‐back working memory paradigm: A meta‐analysis of normative functional neuroimaging studiesHuman Brain Mapping, 2005
- Trail Making Test A and B: Normative data stratified by age and educationArchives of Clinical Neuropsychology, 2004
- Whole Brain SegmentationNeuron, 2002
- In vivo 1H NMR spectroscopy of the human brain at 7 TMagnetic Resonance in Medicine, 2001
- Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer TypeInternational Psychogeriatrics, 1997
- Estimation of metabolite concentrations from localized in vivo proton NMR spectraMagnetic Resonance in Medicine, 1993
- Apathy following cerebrovascular lesions.Stroke, 1993
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- “Mini-mental state”Journal of Psychiatric Research, 1975